Anti-inflammatory composition and use thereof

Abstract

The present application provides an anti-inflammatory composition, which includes palmitoyl tetrapeptide-7, acetylated hyaluronic acid or its salt, and hydrolyzed hyaluronic acid or its salt having a molecular weight of less than 50 kDa, wherein the mass ratio of the hydrolyzed hyaluronic acid or its salt to the acetylated hyaluronic acid or its salt is greater than 1:1. The anti-inflammatory composition of the present application can not only overcome the anti-inflammatory antagonism between acetylated hyaluronic acid or its salt and palmitoyl tetrapeptide-7, but also can better inhibit the expression of inflammatory factors compared to the use of each component alone, and has an anti-inflammatory synergistic effect.

Description

Technical Field

[0001] The present application belongs to the field of cosmetic technology, and specifically, relates to an anti-inflammatory composition and uses thereof. Background Art

[0002] In recent years, acetylated hyaluronic acid (abbreviated as AcHA) has been increasingly used in skin care product formulations because acetylation modification can improve the bioavailability of HA and produce additional biological effects, such as reducing the expression of MMP and slowing down the decomposition of ECM.

[0003] Palmitoyl tetrapeptide-7 (abbreviated as PT-7, amino sequence: Pal-Gly-Gln-Pro-Arg-OH) is a peptide bonded peptide composed of four amino acids, which has the effect of inhibiting the expression of inflammatory factors. Summary of the invention

[0004] However, the inventors of the present application have found that when AcHA and PT-7 are used in combination, there will be a serious antagonistic effect on the anti-inflammatory effect. In response to this problem, the present application provides an anti-inflammatory composition, which can not only overcome the antagonistic effect between AcHA and PT-7, but also better inhibit the expression of inflammatory factors compared to using each component alone, and has a synergistic anti-inflammatory effect.

[0005] Specifically, this application involves the following aspects:

[0006] 1. An anti-inflammatory composition, comprising palmitoyl tetrapeptide-7, acetylated hyaluronic acid or a salt thereof, and hydrolyzed hyaluronic acid or a salt thereof having a molecular weight of less than 50 kDa, wherein the mass ratio of the hydrolyzed hyaluronic acid or a salt thereof to the acetylated hyaluronic acid or a salt thereof is greater than 1:1.

[0007] 2. The anti-inflammatory composition according to item 1, wherein the mass ratio of the hydrolyzed hyaluronic acid or its salt to the acetylated hyaluronic acid or its salt is 1.5:1-100:1.

[0008] 3. The anti-inflammatory composition according to any one of items 1 to 2, wherein the mass ratio of the sum of the acetylated hyaluronic acid or its salt and the hydrolyzed hyaluronic acid or its salt to palmitoyl tetrapeptide-7 is 1:10-10:1.

[0009] 4. The anti-inflammatory composition according to item 3, wherein the mass ratio of the sum of the acetylated hyaluronic acid or its salt and the hydrolyzed hyaluronic acid or its salt to palmitoyl tetrapeptide-7 is 1:5-5:1.

[0010] 5. The anti-inflammatory composition according to any one of items 1 to 4, wherein the molecular weight of the hydrolyzed hyaluronic acid or its salt is 1000Da-20kDa.

[0011] 6. Use of the anti-inflammatory composition described in items 1 to 5 in the preparation of anti-inflammatory products.

[0012] 7. Use of the anti-inflammatory composition described in items 1 to 5 in the preparation of cosmetics.

[0013] 8. Use of hydrolyzed hyaluronic acid or a salt thereof having a molecular weight of less than 50 kDa in reducing the antagonistic effect between acetylated hyaluronic acid or a salt thereof and palmitoyl tetrapeptide-7.

[0014] 9. The use according to item 8, wherein the mass ratio of the hydrolyzed hyaluronic acid or its salt to the acetylated hyaluronic acid or its salt is greater than 1:1;

[0015] Preferably, the mass ratio of the hydrolyzed hyaluronic acid or its salt to the acetylated hyaluronic acid or its salt is 1.5:1-100:1.

[0016] 10. The use according to item 8 or 9, wherein the mass ratio of the sum of the acetylated hyaluronic acid or its salt and the hydrolyzed hyaluronic acid or its salt to palmitoyl tetrapeptide-7 is 1:10-10:1;

[0017] Preferably, the mass ratio of the sum of the acetylated hyaluronic acid or its salt and the hydrolyzed hyaluronic acid or its salt to palmitoyl tetrapeptide-7 is 1:5-5:1;

[0018] More preferably, the molecular weight of the hydrolyzed hyaluronic acid or its salt is 1000Da-20kDa. DETAILED DESCRIPTION

[0019] The present application is further described below in conjunction with examples. It should be understood that the examples are only used to further describe and illustrate the present application and are not used to limit the present application.

[0020] Unless otherwise defined, the technical and scientific terms in this specification have the same meaning as those generally understood by those skilled in the art. Although similar or identical methods and materials as described herein may be used in experiments or practical applications, materials and methods are described herein below. In the event of a conflict, the present specification including the definitions therein shall prevail. In addition, materials, methods and examples are provided for illustration only and are not restrictive. The present application is further described below in conjunction with specific embodiments, but is not intended to limit the scope of the present application.

[0021] The present application provides an anti-inflammatory composition, which includes palmitoyl tetrapeptide-7, acetylated hyaluronic acid or a salt thereof, and hydrolyzed hyaluronic acid or a salt thereof with a molecular weight less than 50 kDa, wherein the mass ratio of the hydrolyzed hyaluronic acid or a salt thereof to the acetylated hyaluronic acid or a salt thereof is greater than 1:1.

[0022] Among them, the hydrolyzed hyaluronic acid or its salt can be, for example, 49kDa, 48kDa, 47kDa, 46kDa, 45kDa, 44kDa, 43kDa, 42kDa, 41kDa, 40kDa, 39kDa, 38kDa, 37kDa, 36kDa, 35kDa, 34kDa, 33kDa, 32kDa, 31kDa, 30kDa, 29kDa, 28kDa, 27kDa, 26kDa kDa, 25 kDa, 24 kDa, 23 kDa, 22 kDa, 21 kDa, 20 kDa, 19 kDa, 18 kDa, 17 kDa, 16 kDa, 15 kDa, 14 kDa, 13 kDa, 12 kDa, 11 kDa, 10 kDa, 9 kDa, 8 kDa, 7 kDa, 6 kDa, 5 kDa, 4 kDa, 3 kDa, 2 kDa, 1 kDa, etc. or any value in between these values.

[0023] In a specific embodiment, the molecular weight of the hydrolyzed hyaluronic acid or its salt is 1000Da-20kDa.

[0024] In a specific embodiment, the molecular weight of the hydrolyzed hyaluronic acid or its salt is 1000Da-15kDa.

[0025] The acetylated hyaluronic acid or its salt used in the present application may be various acetylated hyaluronic acids or its salts known in the art. For example, the molecular weight of the acetylated hyaluronic acid or its salt may be 10 kDa-100 kDa.

[0026] The mass ratio of the hydrolyzed hyaluronic acid or its salt to the acetylated hyaluronic acid or its salt is greater than 1:1, for example, it can be 1.1:1, 1.5:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 20:1, 25:1, 30:1, 35:1, 40:1 1, 45:1, 50:1, 55:1, 60:1, 65:1, 70:1, 75:1, 80:1, 85:1, 90:1, 95:1, 100:1, 110:1, 120:1, 130:1, 140:1, 150:1, 160:1, 170:1, 180:1, 190:1, 200:1 etc. or any value in between these values.

[0027] In a specific embodiment, the mass ratio of the hydrolyzed hyaluronic acid or its salt to the acetylated hyaluronic acid or its salt is 1.5:1-100:1.

[0028] In a specific embodiment, the mass ratio of the hydrolyzed hyaluronic acid or its salt to the acetylated hyaluronic acid or its salt is 1.5:1-50:1.

[0029] In a specific embodiment, the mass ratio of the sum of the acetylated hyaluronic acid or its salt and the hydrolyzed hyaluronic acid or its salt to palmitoyl tetrapeptide-7 is 1:10-10:1, for example, it can be 1:10, 2:10 (1:5), 3:10, 4:10 (2:5), 5:10 (1:2), 6:10 (3:5), 7:10, 8:10 (4:5), 9:10, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, etc. or any value between these values.

[0030] In a specific embodiment, the mass ratio of the sum of the acetylated hyaluronic acid or its salt and the hydrolyzed hyaluronic acid or its salt to palmitoyl tetrapeptide-7 is 1:5-5:1.

[0031] In a specific embodiment, the anti-inflammatory composition comprises palmitoyl tetrapeptide-7, acetylated hyaluronic acid or a salt thereof, and hydrolyzed hyaluronic acid or a salt thereof having a molecular weight of less than 50 kDa, wherein the mass ratio of the hydrolyzed hyaluronic acid or a salt thereof to the acetylated hyaluronic acid or a salt thereof is greater than 1: 1. The mass ratio of the sum of the acetylated hyaluronic acid or a salt thereof and the hydrolyzed hyaluronic acid or a salt thereof to palmitoyl tetrapeptide-7 is 1:10-10:1.

[0032] In a specific embodiment, the anti-inflammatory composition comprises palmitoyl tetrapeptide-7, acetylated hyaluronic acid or a salt thereof, and hydrolyzed hyaluronic acid or a salt thereof having a molecular weight of 1000Da-20kDa, wherein the mass ratio of the hydrolyzed hyaluronic acid or a salt thereof to the acetylated hyaluronic acid or a salt thereof is 1.5: 1-100: 1. The mass ratio of the sum of the acetylated hyaluronic acid or a salt thereof and the hydrolyzed hyaluronic acid or a salt thereof to palmitoyl tetrapeptide-7 is 1: 10-10: 1.

[0033] In a specific embodiment, the anti-inflammatory composition comprises palmitoyl tetrapeptide-7, acetylated hyaluronic acid or a salt thereof, and hydrolyzed hyaluronic acid or a salt thereof having a molecular weight of 1000Da-10kDa, wherein the mass ratio of the hydrolyzed hyaluronic acid or a salt thereof to the acetylated hyaluronic acid or a salt thereof is 2:1-11:1. The mass ratio of the sum of the acetylated hyaluronic acid or a salt thereof and the hydrolyzed hyaluronic acid or a salt thereof to palmitoyl tetrapeptide-7 is 1:5-5:1.

[0034] In a specific embodiment, the anti-inflammatory composition comprises palmitoyl tetrapeptide-7, acetylated hyaluronic acid or a salt thereof, and hydrolyzed hyaluronic acid or a salt thereof having a molecular weight of 3000 Da, wherein the mass ratio of the hydrolyzed hyaluronic acid or a salt thereof to the acetylated hyaluronic acid or a salt thereof is 2: 1. The mass ratio of the sum of the acetylated hyaluronic acid or a salt thereof and the hydrolyzed hyaluronic acid or a salt thereof to palmitoyl tetrapeptide-7 is 4: 1.

[0035] In a specific embodiment, the anti-inflammatory composition comprises palmitoyl tetrapeptide-7, acetylated hyaluronic acid or a salt thereof, and hydrolyzed hyaluronic acid or a salt thereof having a molecular weight of 3000 Da, wherein the mass ratio of the hydrolyzed hyaluronic acid or a salt thereof to the acetylated hyaluronic acid or a salt thereof is 11: 1. The mass ratio of the sum of the acetylated hyaluronic acid or a salt thereof and the hydrolyzed hyaluronic acid or a salt thereof to palmitoyl tetrapeptide-7 is 4: 1.

[0036] In a specific embodiment, the anti-inflammatory composition comprises palmitoyl tetrapeptide-7, acetylated hyaluronic acid or a salt thereof, and hydrolyzed hyaluronic acid or a salt thereof having a molecular weight of 1500 Da, wherein the mass ratio of the hydrolyzed hyaluronic acid or a salt thereof to the acetylated hyaluronic acid or a salt thereof is 11: 1. The mass ratio of the sum of the acetylated hyaluronic acid or a salt thereof and the hydrolyzed hyaluronic acid or a salt thereof to palmitoyl tetrapeptide-7 is 4: 1.

[0037] In a specific embodiment, the anti-inflammatory composition comprises palmitoyl tetrapeptide-7, acetylated hyaluronic acid or a salt thereof, and hydrolyzed hyaluronic acid or a salt thereof having a molecular weight of 10,000 Da, wherein the mass ratio of the hydrolyzed hyaluronic acid or a salt thereof to the acetylated hyaluronic acid or a salt thereof is 11: 1. The mass ratio of the sum of the acetylated hyaluronic acid or a salt thereof and the hydrolyzed hyaluronic acid or a salt thereof to palmitoyl tetrapeptide-7 is 4: 1.

[0038] In a specific embodiment, the anti-inflammatory composition comprises palmitoyl tetrapeptide-7, acetylated hyaluronic acid or a salt thereof, and hydrolyzed hyaluronic acid or a salt thereof having a molecular weight of 3000 Da, wherein the mass ratio of the hydrolyzed hyaluronic acid or a salt thereof to the acetylated hyaluronic acid or a salt thereof is 2: 1. The mass ratio of the sum of the acetylated hyaluronic acid or a salt thereof and the hydrolyzed hyaluronic acid or a salt thereof to palmitoyl tetrapeptide-7 is 1:4.

[0039] In a specific embodiment, the anti-inflammatory composition comprises palmitoyl tetrapeptide-7, acetylated hyaluronic acid or a salt thereof, and hydrolyzed hyaluronic acid or a salt thereof having a molecular weight of 3000 Da, wherein the mass ratio of the hydrolyzed hyaluronic acid or a salt thereof to the acetylated hyaluronic acid or a salt thereof is 5: 1. The mass ratio of the sum of the acetylated hyaluronic acid or a salt thereof and the hydrolyzed hyaluronic acid or a salt thereof to palmitoyl tetrapeptide-7 is 1:4.

[0040] In a specific embodiment, the anti-inflammatory composition is composed of palmitoyl tetrapeptide-7, acetylated hyaluronic acid or its salt, and hydrolyzed hyaluronic acid or its salt having a molecular weight of less than 50 kDa, and the mass ratio of the hydrolyzed hyaluronic acid or its salt to the acetylated hyaluronic acid or its salt is greater than 1:1.

[0041] In a specific embodiment, the anti-inflammatory composition is composed of palmitoyl tetrapeptide-7, acetylated hyaluronic acid or a salt thereof, and hydrolyzed hyaluronic acid or a salt thereof having a molecular weight of less than 50 kDa, wherein the mass ratio of the hydrolyzed hyaluronic acid or a salt thereof to the acetylated hyaluronic acid or a salt thereof is greater than 1: 1. The mass ratio of the sum of the acetylated hyaluronic acid or a salt thereof and the hydrolyzed hyaluronic acid or a salt thereof to palmitoyl tetrapeptide-7 is 1:10-10:1.

[0042] In a specific embodiment, the anti-inflammatory composition is composed of palmitoyl tetrapeptide-7, acetylated hyaluronic acid or a salt thereof, and hydrolyzed hyaluronic acid or a salt thereof having a molecular weight of less than 50 kDa, wherein the mass ratio of the hydrolyzed hyaluronic acid or a salt thereof to the acetylated hyaluronic acid or a salt thereof is 1.5: 1-100: 1. The mass ratio of the sum of the acetylated hyaluronic acid or a salt thereof and the hydrolyzed hyaluronic acid or a salt thereof to palmitoyl tetrapeptide-7 is 1: 10-10: 1.

[0043] In a specific embodiment, the anti-inflammatory composition is composed of palmitoyl tetrapeptide-7, acetylated hyaluronic acid or a salt thereof, and hydrolyzed hyaluronic acid or a salt thereof having a molecular weight of less than 50 kDa, wherein the mass ratio of the hydrolyzed hyaluronic acid or a salt thereof to the acetylated hyaluronic acid or a salt thereof is 2: 1-11: 1. The mass ratio of the sum of the acetylated hyaluronic acid or a salt thereof and the hydrolyzed hyaluronic acid or a salt thereof to palmitoyl tetrapeptide-7 is 1: 5-5: 1.

[0044] In a specific embodiment, the anti-inflammatory composition is composed of palmitoyl tetrapeptide-7, acetylated hyaluronic acid or a salt thereof, and hydrolyzed hyaluronic acid or a salt thereof having a molecular weight of less than 50 kDa, wherein the mass ratio of the hydrolyzed hyaluronic acid or a salt thereof to the acetylated hyaluronic acid or a salt thereof is 2: 1. The mass ratio of the sum of the acetylated hyaluronic acid or a salt thereof and the hydrolyzed hyaluronic acid or a salt thereof to palmitoyl tetrapeptide-7 is 4: 1.

[0045] In a specific embodiment, the anti-inflammatory composition is composed of palmitoyl tetrapeptide-7, acetylated hyaluronic acid or a salt thereof, and hydrolyzed hyaluronic acid or a salt thereof having a molecular weight of less than 50 kDa, wherein the mass ratio of the hydrolyzed hyaluronic acid or a salt thereof to the acetylated hyaluronic acid or a salt thereof is 11: 1. The mass ratio of the sum of the acetylated hyaluronic acid or a salt thereof and the hydrolyzed hyaluronic acid or a salt thereof to palmitoyl tetrapeptide-7 is 4: 1.

[0046] In a specific embodiment, the anti-inflammatory composition is composed of palmitoyl tetrapeptide-7, acetylated hyaluronic acid or a salt thereof, and hydrolyzed hyaluronic acid or a salt thereof having a molecular weight of less than 50 kDa, wherein the mass ratio of the hydrolyzed hyaluronic acid or a salt thereof to the acetylated hyaluronic acid or a salt thereof is 11: 1. The mass ratio of the sum of the acetylated hyaluronic acid or a salt thereof and the hydrolyzed hyaluronic acid or a salt thereof to palmitoyl tetrapeptide-7 is 4: 1.

[0047] In a specific embodiment, the anti-inflammatory composition is composed of palmitoyl tetrapeptide-7, acetylated hyaluronic acid or a salt thereof, and hydrolyzed hyaluronic acid or a salt thereof having a molecular weight of less than 50 kDa, wherein the mass ratio of the hydrolyzed hyaluronic acid or a salt thereof to the acetylated hyaluronic acid or a salt thereof is 11: 1. The mass ratio of the sum of the acetylated hyaluronic acid or a salt thereof and the hydrolyzed hyaluronic acid or a salt thereof to palmitoyl tetrapeptide-7 is 4: 1.

[0048] In a specific embodiment, the anti-inflammatory composition is composed of palmitoyl tetrapeptide-7, acetylated hyaluronic acid or a salt thereof, and hydrolyzed hyaluronic acid or a salt thereof having a molecular weight of less than 50 kDa, wherein the mass ratio of the hydrolyzed hyaluronic acid or a salt thereof to the acetylated hyaluronic acid or a salt thereof is 2: 1. The mass ratio of the sum of the acetylated hyaluronic acid or a salt thereof and the hydrolyzed hyaluronic acid or a salt thereof to palmitoyl tetrapeptide-7 is 1:4.

[0049] In a specific embodiment, the anti-inflammatory composition is composed of palmitoyl tetrapeptide-7, acetylated hyaluronic acid or a salt thereof, and hydrolyzed hyaluronic acid or a salt thereof having a molecular weight of less than 50 kDa, wherein the mass ratio of the hydrolyzed hyaluronic acid or a salt thereof to the acetylated hyaluronic acid or a salt thereof is 5: 1. The mass ratio of the sum of the acetylated hyaluronic acid or a salt thereof and the hydrolyzed hyaluronic acid or a salt thereof to palmitoyl tetrapeptide-7 is 1:4.

[0050] The present application also provides use of any one of the above-mentioned anti-inflammatory compositions in anti-inflammation.

[0051] The present application also provides use of any one of the above anti-inflammatory compositions in the preparation of anti-inflammatory products.

[0052] The present application also provides use of any one of the above anti-inflammatory compositions in the preparation of cosmetics.

[0053] The present application also provides the use of hydrolyzed hyaluronic acid or a salt thereof having a molecular weight of less than 50 kDa in reducing the anti-inflammatory antagonism between acetylated hyaluronic acid or a salt thereof and palmitoyl tetrapeptide-7.

[0054] Among them, the specific molecular weight of the hydrolyzed hyaluronic acid or its salt, the mass ratio between the hydrolyzed hyaluronic acid or its salt and the acetylated hyaluronic acid or its salt, and the mass ratio between the sum of the acetylated hyaluronic acid or its salt and the hydrolyzed hyaluronic acid or its salt and palmitoyl tetrapeptide-7 are as described above for the anti-inflammatory composition.

[0055] The anti-inflammatory composition of the present application, by using hydrolyzed hyaluronic acid or its salt with a molecular weight of less than 50 kDa and controlling the mass ratio of hydrolyzed hyaluronic acid or its salt to acetylated hyaluronic acid or its salt to be greater than 1:1, can overcome the anti-inflammatory antagonism between AcHA and PT-7, and compared with the use of each component alone, can better inhibit the expression of inflammatory factors and has a synergistic anti-inflammatory effect.

[0056] Example

[0057] The raw materials and equipment information used in the examples of this application are shown in Tables 1 and 2.

[0058] Table 1

[0059]

[0060] Table 2

[0061] Main Equipment Manufacturer & Model <![CDATA[CO2 Incubator]]> Thermo, 150I Clean bench Sujing Antai, SW-CJ-1F UVA Irradiator Boxi Biotechnology Constant temperature box Tester Ordinary PCR instrument Boge Fluorescence quantitative PCR instrument BioRad, CFX-96

[0062] Example 1

[0063] PT-7, UMW-HA and AcHA were weighed and dissolved in a culture medium solution to obtain a composition, wherein the content of PT-7 in the composition was 30 μg / ml, the content of UMW-HA was 80 μg / ml, and the content of AcHA was 40 μg / ml.

[0064] Wherein, the culture medium solution is prepared as follows:

[0065] DMEM stock solution: 89%

[0066] FBS fetal bovine serum stock solution: 10%

[0067] PS double antibody raw material solution: 1%.

[0068] Example 2

[0069] PT-7, UMW-HA and AcHA were weighed and dissolved in a culture medium solution (the same preparation method as in Example 1) to obtain a composition. The content of PT-7 in the composition was 30 μg / ml, the content of UMW-HA was 110 μg / ml, and the content of AcHA was 10 μg / ml.

[0070] Example 3

[0071] PT-7, UMW-HA-2 and AcHA were weighed and dissolved in a culture medium solution (the same preparation method as in Example 1) to obtain a composition. The content of PT-7 in the composition was 30 μg / ml, the content of UMW-HA-2 was 110 μg / ml, and the content of AcHA was 10 μg / ml.

[0072] Example 4

[0073] PT-7, UMW-HA-3 and AcHA were weighed and dissolved in a culture medium solution (the same preparation method as in Example 1) to obtain a composition. The content of PT-7 in the composition was 30 μg / ml, the content of UMW-HA-3 was 110 μg / ml, and the content of AcHA was 10 μg / ml.

[0074] Example 5

[0075] PT-7, UMW-HA and AcHA were weighed and dissolved in a culture medium solution (the same preparation method as in Example 1) to obtain a composition. The content of PT-7 in the composition was 120 μg / ml, the content of UMW-HA was 20 μg / ml, and the content of AcHA was 10 μg / ml.

[0076] Example 6

[0077] PT-7, UMW-HA and AcHA were weighed and dissolved in a culture medium solution (the same preparation method as in Example 1) to obtain a composition. The content of PT-7 in the composition was 120 μg / ml, the content of UMW-HA was 25 μg / ml, and the content of AcHA was 5 μg / ml.

[0078] Example 7

[0079] PT-7, UMW-HA and AcHA were weighed and dissolved in a culture medium solution (the same preparation method as in Example 1) to obtain a composition. The content of PT-7 in the composition was 135 μg / ml, the content of UMW-HA was 10 μg / ml, and the content of AcHA was 5 μg / ml.

[0080] Comparative Example 1

[0081] PT-7 was dissolved in a culture medium solution (the same preparation method as in Example 1) to prepare a PT-7 solution with a concentration of 150 g / ml.

[0082] Comparative Example 2

[0083] UMW-HA was dissolved in a culture medium solution (the same preparation method as in Example 1) to prepare a UMW-HA solution with a concentration of 150 g / ml.

[0084] Comparative Example 3

[0085] LMW-HA was dissolved in a culture medium solution (the same preparation method as in Example 1) to prepare a LMW-HA solution with a concentration of 150 g / ml.

[0086] Comparative Example 4

[0087] AcHA was dissolved in a culture medium solution (the same preparation method as in Example 1) to prepare an AcHA solution with a concentration of 150 g / ml.

[0088] Comparative Example 5

[0089] PT-7 and AcHA were weighed and dissolved in a culture medium solution (the same preparation method as in Example 1) to obtain a composition in which the content of PT-7 was 120 μg / ml and the content of AcHA was 30 μg / ml.

[0090] Comparative Example 6

[0091] PT-7 and AcHA were weighed and dissolved in a culture medium solution (the same preparation method as in Example 1) to obtain a composition in which the content of PT-7 was 30 μg / ml and the content of AcHA was 120 μg / ml.

[0092] Comparative Example 7

[0093] PT-7, LMW-HA and AcHA were weighed and dissolved in a culture medium solution (the same preparation method as in Example 1) to obtain a composition. The content of PT-7 in the composition was 30 μg / ml, the content of LMW-HA was 80 μg / ml, and the content of AcHA was 40 μg / ml.

[0094] Comparative Example 8

[0095] PT-7, LMW-HA and AcHA were weighed and dissolved in a culture medium solution (the same preparation method as in Example 1) to obtain a composition. The content of PT-7 in the composition was 120 μg / ml, the content of LMW-HA was 20 μg / ml, and the content of AcHA was 10 μg / ml.

[0096] Comparative Example 9

[0097] PT-7, UMW-HA and AcHA were weighed and dissolved in a culture medium solution (the same preparation method as in Example 1) to obtain a composition. The content of PT-7 in the composition was 30 μg / ml, the content of UMW-HA was 40 μg / ml, and the content of AcHA was 80 μg / ml.

[0098] Comparative Example 10

[0099] PT-7, UMW-HA and AcHA were weighed and dissolved in a culture medium solution (the same preparation method as in Example 1) to obtain a composition. The content of PT-7 in the composition was 30 μg / ml, the content of UMW-HA was 60 μg / ml, and the content of AcHA was 60 μg / ml.

[0100] Test example

[0101] The samples prepared in the above examples and comparative examples were used in cells to perform IL-6 expression test.

[0102] 1) Cell seeding: 4×10 4 Fibroblasts were seeded into 24-well plates at a seeding density of 100 cells / well and incubated overnight in an incubator (37° C., 5% CO 2 ).

[0103] 2) Administration: When the cell plating rate in the 24-well plate reaches 40% to 60%, group administration is carried out. The samples prepared in the above embodiments and comparative examples are used as the working solution of the test substance. 2 mL of sample is added to each well, and 6 replicate wells are set up in each group. After the administration is completed, the 6-well plate is placed in an incubator (37°C, 5% CO2) and cultured for 24 hours. Among them, the blank control group does not add any sample.

[0104] 3) UVA irradiation: According to the experimental grouping, the group that needs UVA irradiation is irradiated with 30J / cm 2 The cells were irradiated with UVA and placed in an incubator (37°C, 5% CO2) for 24 h.

[0105] 4) Collect cells: After culturing for 24 hours, collect the cell supernatant, wash twice with 1 mL / well PBS, add 1 mL RNAiso Plus to each well, pipette and lyse the cells, and collect the samples.

[0106] 5) Gene expression detection: After treating fibroblasts with RNAiso Plus, samples were collected and RNA extraction, reverse transcription and fluorescence quantitative PCR were performed according to the instructions of the kit to determine the Ct value of each well.

[0107] 6) Statistical analysis of results: The results of each group of experiments were the average Ct values ​​of 6 replicate wells. The average Ct value was multiplied by 2 -△△Ct Methods Data were processed and the results were normalized with the blank control group as 1.0.

[0108] The detection results of IL-6 expression and the contents of specific components in the above examples and comparative examples are shown in Table 3.

[0109] Table 3

[0110]

[0111]

Claims

1. An anti-inflammatory composition comprising palmitoyl tetrapeptide-7, acetylated hyaluronic acid or a salt thereof, and hydrolyzed hyaluronic acid or a salt thereof having a molecular weight of less than or equal to 20 kDa, wherein the mass ratio of the hydrolyzed hyaluronic acid or a salt thereof to the acetylated hyaluronic acid or a salt thereof is 1.5:1-100:1; The mass ratio of the sum of the acetylated hyaluronic acid or its salt and the hydrolyzed hyaluronic acid or its salt to palmitoyl tetrapeptide-7 is 1:10-10:

1.

2. The anti-inflammatory composition according to claim 1, wherein the mass ratio of the sum of the acetylated hyaluronic acid or its salt and the hydrolyzed hyaluronic acid or its salt to palmitoyl tetrapeptide-7 is 1:5-5:

1.

3. The anti-inflammatory composition according to claim 1 or 2, wherein the molecular weight of the hydrolyzed hyaluronic acid or its salt is 1000Da-20kDa.

4. Use of the anti-inflammatory composition according to any one of claims 1 to 3 in the preparation of anti-inflammatory products.

5. Use of the anti-inflammatory composition according to any one of claims 1 to 3 in the preparation of cosmetics.

6. Use of a hydrolyzed hyaluronic acid or a salt thereof having a molecular weight of less than or equal to 20 kDa in the preparation of a product for reducing the anti-inflammatory antagonism between acetylated hyaluronic acid or a salt thereof and palmitoyl tetrapeptide-7, wherein the mass ratio of the hydrolyzed hyaluronic acid or a salt thereof to the acetylated hyaluronic acid or a salt thereof is 1.5:1-100:1; The mass ratio of the sum of the acetylated hyaluronic acid or its salt and the hydrolyzed hyaluronic acid or its salt to palmitoyl tetrapeptide-7 is 1:10-10:

1.

7. The use according to claim 6, wherein the mass ratio of the sum of the acetylated hyaluronic acid or its salt and the hydrolyzed hyaluronic acid or its salt to palmitoyl tetrapeptide-7 is 1:5-5:

1.

8. The use according to claim 6 or 7, wherein the molecular weight of the hydrolyzed hyaluronic acid or its salt is 1000Da-20kDa.

Images